NASDAQ:DEPO - Depomed Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: N/A
Consensus Price Target: $0.00
Forecasted Upside: -100.00 %
Number of Analysts: 0
Breakdown:
0 Sell Ratings
0 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$7.30 As of 08/14/2018 01:00 AM ET

+0.30 (1.20%)

Get New Depomed Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for DEPO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DEPO

^$0.00

▼ -100.00% Downside Potential

This price target is based on 0 analysts offering 12 month price targets for Depomed in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $7.30.

Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Depomed. This rating has held steady since August 2019, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/31/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/30/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/29/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/27/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/25/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/25/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/24/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/24/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
8/8/2018	Royal Bank of Canada	Set Price Target	Hold	$8.00	High
7/9/2018	Janney Montgomery Scott	Upgrade	Neutral ➝ Buy	$7.00 ➝ $10.00	Medium
3/23/2018	Mizuho	Reiterated Rating	Buy	$9.00	High
3/2/2018	Roth Capital	Set Price Target	Buy	$10.00	Medium
3/1/2018	Piper Jaffray Companies	Reiterated Rating	Hold	$8.00	Medium
12/7/2017	Royal Bank of Canada	Set Price Target	Hold	$9.00	Medium
12/7/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$9.00	High
12/5/2017	Mizuho	Upgrade	Neutral ➝ Buy	$9.00	High
11/10/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$5.00	N/A
11/10/2017	UBS Group	Boost Price Target	Neutral	$6.00 ➝ $7.00	N/A
11/9/2017	Morgan Stanley	Upgrade	Underweight ➝ Equal Weight		N/A
11/8/2017	Royal Bank of Canada	Lower Price Target	Sector Perform	$8.00 ➝ $6.00	N/A
10/27/2017	Royal Bank of Canada	Set Price Target	Hold	$8.00	N/A
10/20/2017	Royal Bank of Canada	Set Price Target	Hold	$10.00	N/A
10/15/2017	Piper Jaffray Companies	Set Price Target	Hold	$9.00	N/A
10/13/2017	Mizuho	Reiterated Rating	Neutral	$11.00 ➝ $6.00	N/A
9/10/2017	Piper Jaffray Companies	Reiterated Rating	Hold	$9.00	High
8/9/2017	Piper Jaffray Companies	Reiterated Rating	Neutral	$10.00 ➝ $9.00	Medium
8/8/2017	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$12.00 ➝ $5.00	High
8/8/2017	Royal Bank of Canada	Lower Price Target	Sector Perform ➝ Sector Perform	$13.00 ➝ $10.00	High
8/8/2017	Janney Montgomery Scott	Downgrade	Buy ➝ Neutral	$18.00 ➝ $8.00	High
7/16/2017	Royal Bank of Canada	Set Price Target	Hold	$13.00	Low
6/13/2017	Royal Bank of Canada	Reiterated Rating	Hold	$13.00	Low
5/25/2017	Mizuho	Lower Price Target	Neutral	$13.00 ➝ $11.00	Medium
5/15/2017	Cantor Fitzgerald	Set Price Target	Hold	$14.00	Medium
5/10/2017	Royal Bank of Canada	Lower Price Target	Sector Perform	$19.00 ➝ $13.00	Low
5/10/2017	Piper Jaffray Companies	Upgrade	Underweight ➝ Neutral	$11.00 ➝ $10.00	High
4/11/2017	Janney Montgomery Scott	Reiterated Rating	Buy	$26.00	Low
3/30/2017	JMP Securities	Reiterated Rating	Outperform	$30.00 ➝ $16.00	High
3/29/2017	Janney Montgomery Scott	Reiterated Rating	Buy	$26.00	High
3/29/2017	Royal Bank of Canada	Lower Price Target	Sector Perform ➝ Sector Perform	$22.00 ➝ $19.00	High
3/29/2017	Cantor Fitzgerald	Reiterated Rating	Hold	$19.00	High
3/29/2017	Mizuho	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $13.00	Low
3/25/2017	Royal Bank of Canada	Set Price Target	Hold	$22.00	Low
3/1/2017	Cantor Fitzgerald	Set Price Target	Hold	$23.00 ➝ $19.00	N/A
2/27/2017	Janney Montgomery Scott	Reiterated Rating	Buy		N/A
2/23/2017	Royal Bank of Canada	Reiterated Rating	Sector Perform	$22.00	N/A
2/20/2017	Mizuho	Downgrade	Buy ➝ Neutral		N/A
2/18/2017	Roth Capital	Set Price Target	Buy	$24.00	N/A
2/14/2017	Mizuho	Downgrade	Buy ➝ Neutral	$24.00 ➝ $17.00	N/A
1/11/2017	Cantor Fitzgerald	Set Price Target	Hold	$23.00	N/A
12/12/2016	Roth Capital	Set Price Target	Buy	$27.00	N/A
12/12/2016	Piper Jaffray Companies	Downgrade	Neutral ➝ Underweight	$17.00 ➝ $14.00	N/A
12/4/2016	Roth Capital	Set Price Target	Buy	$27.00	N/A
11/28/2016	Roth Capital	Set Price Target	Buy	$27.00	N/A
11/9/2016	Mizuho	Upgrade	Neutral ➝ Buy	$27.00 ➝ $24.00	N/A
11/8/2016	SVB Leerink	Set Price Target	Buy	$22.00	N/A
11/8/2016	Mizuho	Reiterated Rating	Hold	$27.00	N/A
11/8/2016	Cantor Fitzgerald	Downgrade	Buy ➝ Hold	$25.00 ➝ $23.00	N/A
10/30/2016	Roth Capital	Set Price Target	Buy	$28.00	N/A
10/21/2016	Roth Capital	Set Price Target	Buy	$28.00	N/A
10/18/2016	Mizuho	Reiterated Rating	Hold	$27.00	N/A
10/17/2016	Janney Montgomery Scott	Reiterated Rating	Buy	$31.00	N/A
10/4/2016	Janney Montgomery Scott	Reiterated Rating	Buy	$28.00 ➝ $31.00	N/A
10/4/2016	Mizuho	Downgrade	Buy ➝ Neutral		N/A
10/3/2016	Mizuho	Downgrade	Buy ➝ Neutral	$27.00	N/A
10/3/2016	UBS Group	Reiterated Rating	Neutral	$20.00 ➝ $26.00	N/A
10/2/2016	SVB Leerink	Reiterated Rating	Buy		N/A
9/28/2016	Janney Montgomery Scott	Reiterated Rating	Buy	$28.00	N/A
9/23/2016	Royal Bank of Canada	Reiterated Rating	Sector Perform	$22.00	N/A
9/16/2016	Mizuho	Boost Price Target	Buy	$23.00 ➝ $27.00	N/A
9/14/2016	Janney Montgomery Scott	Reiterated Rating	Buy	$28.00	N/A
8/11/2016	Cantor Fitzgerald	Reiterated Rating	Buy		N/A
8/4/2016	Piper Jaffray Companies	Reiterated Rating	Neutral	$18.00 ➝ $19.00	N/A
8/4/2016	JMP Securities	Lower Price Target	Market Outperform	$28.00 ➝ $22.00	N/A
8/4/2016	Janney Montgomery Scott	Reiterated Rating	Buy	$28.00	N/A
8/4/2016	Mizuho	Reiterated Rating	Buy	$23.00	N/A
7/28/2016	Cantor Fitzgerald	Reiterated Rating	Buy	$26.00	N/A
7/27/2016	Piper Jaffray Companies	Downgrade	Overweight ➝ Neutral	$21.00 ➝ $18.00	N/A

(Data available from 7/24/2016 forward)

Assertio Holdings, Inc. engages in the provision of commercial pharmaceutical products. Its commercial portfolio of branded products focuses on the following areas: neurology, hospital, and pain and inflammation. The company was founded on August 7, 1995 and is headquartered in Lake Forest, IL.

Today's Range

Now: $7.30

$7.09

$7.42

50 Day Range

MA: N/A

52 Week Range

Now: $7.30

$4.31

$9.48

Volume

940,193 shs

Average Volume

1,300,311 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Depomed?

The following equities research analysts have issued reports on Depomed in the last twelve months:
View the latest analyst ratings for DEPO.

What is the current price target for Depomed?

0 Wall Street analysts have set twelve-month price targets for Depomed in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Depomed in the next year.
View the latest price targets for DEPO.

What is the current consensus analyst rating for Depomed?

Depomed currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for DEPO.

What other companies compete with Depomed?

Other companies that are similar to Depomed include Johnson & Johnson, Pfizer, Eli Lilly and, AbbVie, Merck & Co., Inc., Bristol-Myers Squibb, Zoetis, Royalty Pharma, Horizon Therapeutics Public, Jazz Pharmaceuticals, Perrigo, Nektar Therapeutics, Pacira BioSciences, Corcept Therapeutics and Supernus Pharmaceuticals.

How do I contact Depomed's investor relations team?

Depomed's physical mailing address is 7999 GATEWAY BLVD. SUITE 300, NEWARK CA, 94560. The specialty pharmaceutical company's listed phone number is (224) 419-7106 and its investor relations email address is [email protected] The official website for Depomed is www.depomedinc.com.